Portfolio

Precision Dermatology

Developer, manufacturer, acquirer and marketer of dermatology products


Develops, manufactures, acquires and markets dermatology-focused specialty pharmaceutical products

PreCision Dermatology, based in Cumberland, Rhode Island, was a fully-integrated dermatology company with a mission to deliver therapies to physicians and patients that demonstrably improve the skin. The company operated in two key segments: Onset Dermatologics, which focused on prescription therapies, and PrecisionMD, which focused on physician dispensed products. The company’s high quality dermatology product portfolio included Locoid®, Hylatopic®, Clindagel®, Celfix DNA® and Relastin®, among others. In February 2014, the company entered into an agreement to be sold to Valeant Pharmaceuticals for $475 million in cash, plus an additional $25 million payable upon the achievement of specific milestones.

Transaction Summary

  • Cumberland, Rhode Island

  • Contact:
    Immanuel Thangaraj
  • Formerly Known As: Precision Dermatology
  • Acquisition
  • Acquired by: Valeant Pharmaceuticals
  • Exit date: July 08, 2014
  • Logo

Related News

“I have been on the Board of Directors of three Essex Woodlands-backed companies, one as Chairman, one as Executive Chairman and one as the only US-based Director. The Essex team is exceptional to work with; they are true partners with the management teams they back. Essex played a key role in helping to build these three rapidly growing companies. I look forward to the fourth deal!”

William W. Crouse

Chairman of the Board of Directors

Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.